Premium
The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women
Author(s) -
Muss Hyman B.
Publication year - 1994
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19941001)74:7+<2165::aid-cncr2820741727>3.0.co;2-6
Subject(s) - medicine , breast cancer , tamoxifen , oncology , chemotherapy , clinical trial , adjuvant therapy , cancer , antiestrogen , disease , randomized controlled trial , gynecology
The management of breast cancer in older women is a major challenge. A metaanalysis of randomized trials of adjuvant therapy in early stage breast cancer has indicated that the use of the antiestrogen tamoxifen improves relapse‐free and overall survival for postmenopausal women, including those older than age 70 years. Tamoxifen therapy is of greatest benefit in patients whose primary lesions are estrogen‐ and progesterone‐receptor positive, but lesser yet still significant benefits are seen in receptor‐negative patients. Adjuvant chemotherapy has only been minimally studied in older women, because earlier trials tended to exclude women older than age 70 years from protocol entry. Trials are needed to explore the role of adjuvant chemotherapy in older women, especially those older than age 70 years. Metastatic breast cancer is incurable. Standard endocrine and chemotherapy regimens may be of great palliative benefit but probably only have modest effects on prolonging survival; older women should be offered such treatment. Initiating treatment for metastases with endocrine therapy does not compromise survival, even when such therapy is given to women who have receptor‐negative malignancy. Patients progressing on endocrine therapy or whose metastatic disease is life‐threatening should be considered for chemotherapy. Older women in generally good health tolerate standard doses of chemotherapy as well as their younger counterparts. Future research in this setting should include clinical trials designed specifically for the elderly and should include quality‐of‐life assessment as a major end point.